[
  {
    "ts": null,
    "headline": "Pfizer Turns To AI Where Drug Risk Is Highest",
    "summary": "Boltz partnership targets faster early decisions",
    "url": "https://finnhub.io/api/news?id=548e09e5434fdae730104ad641ca861f24fb23140af074230b58a425aacec10f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767891557,
      "headline": "Pfizer Turns To AI Where Drug Risk Is Highest",
      "id": 138038459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Boltz partnership targets faster early decisions",
      "url": "https://finnhub.io/api/news?id=548e09e5434fdae730104ad641ca861f24fb23140af074230b58a425aacec10f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Partners with Boltz to Use AI in Drug Discovery",
    "summary": "Collaboration aims to accelerate preclinical research with biomolecular AI models.",
    "url": "https://finnhub.io/api/news?id=1bcac96e3d0ab2c3a163c9d9bf568490b850ca4eda87a7f50ad3a1dd7f97292f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767891212,
      "headline": "Pfizer Partners with Boltz to Use AI in Drug Discovery",
      "id": 138038460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Collaboration aims to accelerate preclinical research with biomolecular AI models.",
      "url": "https://finnhub.io/api/news?id=1bcac96e3d0ab2c3a163c9d9bf568490b850ca4eda87a7f50ad3a1dd7f97292f"
    }
  },
  {
    "ts": null,
    "headline": "Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks",
    "summary": "These high-yielding dividend stocks pay 5% or more, and make for safe income investments to hold on to.",
    "url": "https://finnhub.io/api/news?id=bfa719a7f1934cffde03814d2cac7c5ca497cb8c46ae14f254dd3d4dd5fdf3d7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767890760,
      "headline": "Want Over $2,000 in Dividends Each Year? Invest $12,000 Each Into These 3 Stocks",
      "id": 138038461,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These high-yielding dividend stocks pay 5% or more, and make for safe income investments to hold on to.",
      "url": "https://finnhub.io/api/news?id=bfa719a7f1934cffde03814d2cac7c5ca497cb8c46ae14f254dd3d4dd5fdf3d7"
    }
  },
  {
    "ts": null,
    "headline": "Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?",
    "summary": "Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.",
    "url": "https://finnhub.io/api/news?id=fc555d45be77d8a0280bbabd09941d06dffb52cfac79ea0a7be742cce75e0877",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767882900,
      "headline": "Is LLY's Ventyx Deal Another Attempt at Diversification Beyond GLP-1?",
      "id": 138036586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space intensifies.",
      "url": "https://finnhub.io/api/news?id=fc555d45be77d8a0280bbabd09941d06dffb52cfac79ea0a7be742cce75e0877"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results from the Phase 3 EV-304 clinical trial (also called KEYNOTE-B15). This study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) improves […]",
    "url": "https://finnhub.io/api/news?id=ca03fff7bc368c1e83ac09c9f0a4aa1066ff85a9de0a098b64c2cce3e73a3340",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767881581,
      "headline": "Pfizer, Astellas Report Positive Phase 3 Trial Results for PADCEV Combination in Bladder Cancer Treatment",
      "id": 138036818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the most buzzing stocks to invest in according to hedge funds. Earlier on December 17, Astellas Pharma and Pfizer Inc. (NYSE:PFE) announced positive topline results from the Phase 3 EV-304 clinical trial (also called KEYNOTE-B15). This study showed that the combination of PADCEV (enfortumab vedotin) and Keytruda (pembrolizumab) improves […]",
      "url": "https://finnhub.io/api/news?id=ca03fff7bc368c1e83ac09c9f0a4aa1066ff85a9de0a098b64c2cce3e73a3340"
    }
  },
  {
    "ts": null,
    "headline": "Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy State-of-the-Art Biomolecular AI Foundation Models",
    "summary": "Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists across the company with state-of-the-art biomolecular AI foundation models and generative workflows for small-molecule and biologics design.",
    "url": "https://finnhub.io/api/news?id=ff72a88aa7be42926c5ea3a38ae44166b912690675db721706544b10c17e518e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767880560,
      "headline": "Boltz and Pfizer Announce Strategic Collaboration to Develop and Deploy State-of-the-Art Biomolecular AI Foundation Models",
      "id": 138036819,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. and Boltz, PBC, an applied AI research lab, today announced a strategic collaboration to empower scientists across the company with state-of-the-art biomolecular AI foundation models and generative workflows for small-molecule and biologics design.",
      "url": "https://finnhub.io/api/news?id=ff72a88aa7be42926c5ea3a38ae44166b912690675db721706544b10c17e518e"
    }
  },
  {
    "ts": null,
    "headline": "Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today",
    "summary": "These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors now.",
    "url": "https://finnhub.io/api/news?id=afbb416dd15ba5bc2479b0ad86cc94988321fbff2042899d9506c73b4dfd7046",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767879706,
      "headline": "Fed Governor Wants Huge Rate Cuts This Year: 5 High-Yield Dividend Stocks to Buy Today",
      "id": 138036798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These five high-yield dividend stocks with solid upside potential and Buy ratings make sense for growth and income investors now.",
      "url": "https://finnhub.io/api/news?id=afbb416dd15ba5bc2479b0ad86cc94988321fbff2042899d9506c73b4dfd7046"
    }
  },
  {
    "ts": null,
    "headline": "Biotech Stocks' Dark Winter Is Over. What That Means For Investors.",
    "summary": "The long winter for biotech stocks is over.  Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.  After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.",
    "url": "https://finnhub.io/api/news?id=e8ea41ebef224f9fda023958cdfd9168fa4c948e91a1d23dd0c75f1ea2d84335",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877251,
      "headline": "Biotech Stocks' Dark Winter Is Over. What That Means For Investors.",
      "id": 138036589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The long winter for biotech stocks is over.  Shares have climbed to levels not seen since late 2021, buoyed by eye-popping takeover valuations, trailblazing innovation in battling obesity and cancer, and a surprising, if uneasy, alliance with the Trump administration.  After peaking in February 2021, shares of Investor's Business Daily's Medical-Biomed/Biotech industry group plummeted more than 64% through April 2025.",
      "url": "https://finnhub.io/api/news?id=e8ea41ebef224f9fda023958cdfd9168fa4c948e91a1d23dd0c75f1ea2d84335"
    }
  },
  {
    "ts": null,
    "headline": "Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity",
    "summary": "SAN FRANCISCO, January 08, 2026--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity",
    "url": "https://finnhub.io/api/news?id=a562cb055a056069f3877bca7f055a9a7b877cb0a4deece62190e6a10d7119cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767877200,
      "headline": "Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity",
      "id": 138036822,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, January 08, 2026--Gordian Bio Announces Research Collaboration with Pfizer to Accelerate In Vivo Target Discovery in Obesity",
      "url": "https://finnhub.io/api/news?id=a562cb055a056069f3877bca7f055a9a7b877cb0a4deece62190e6a10d7119cc"
    }
  },
  {
    "ts": null,
    "headline": "Analysis-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
    "summary": "By Michael Erman and Maggie Fick NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S",
    "url": "https://finnhub.io/api/news?id=3caf37cdcc32a90b8ec985e24d96e4a87520ed70855f300994586cff4aee08d0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767871799,
      "headline": "Analysis-Drugmakers brace for Europe pricing fight after Trump's US price-cut deals",
      "id": 138034981,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "By Michael Erman and Maggie Fick NEW YORK/LONDON, Jan 8 (Reuters) - Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S",
      "url": "https://finnhub.io/api/news?id=3caf37cdcc32a90b8ec985e24d96e4a87520ed70855f300994586cff4aee08d0"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's (NYSE:PFE) Dividend Will Be $0.43",
    "summary": "Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March. The dividend...",
    "url": "https://finnhub.io/api/news?id=013eae4ca2b8e49421e669fb9885552901640ada6572653873fa9ce1bd719243",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767866638,
      "headline": "Pfizer's (NYSE:PFE) Dividend Will Be $0.43",
      "id": 138035050,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. ( NYSE:PFE ) has announced that it will pay a dividend of $0.43 per share on the 6th of March. The dividend...",
      "url": "https://finnhub.io/api/news?id=013eae4ca2b8e49421e669fb9885552901640ada6572653873fa9ce1bd719243"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?",
    "summary": "This big pharma stock still faces significant challenges in the new year.",
    "url": "https://finnhub.io/api/news?id=7706d09ec5d5bdbefacc8b2a69c9a7cc04223287b76ace8aa92ddb5073979da1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767863400,
      "headline": "Pfizer's Stock Just Dropped 6%. Can the Pharmaceutical Giant Bounce Back in 2026?",
      "id": 138033379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This big pharma stock still faces significant challenges in the new year.",
      "url": "https://finnhub.io/api/news?id=7706d09ec5d5bdbefacc8b2a69c9a7cc04223287b76ace8aa92ddb5073979da1"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
    "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
    "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767850200,
      "headline": "Healthcare Stocks In Focus: Assessing The Outlook For 2026",
      "id": 138034430,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1487494602/image_1487494602.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "After a prolonged slump, investors are giving the healthcare sector a second look. TD Asset Management's Jacky He discusses potential drivers for biotech and pharmaceutical stocks in 2026.",
      "url": "https://finnhub.io/api/news?id=3274ac6c8006bb91e5a1e993463154bbb35619d530559a7095996210d5b0fa19"
    }
  },
  {
    "ts": null,
    "headline": "1 Stock Under $50 Worth Your Attention and 2 That Underwhelm",
    "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
    "url": "https://finnhub.io/api/news?id=a5b000f119a675be200cdc107286503590cb710304258f4cf0c41eb86cf32b29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767846868,
      "headline": "1 Stock Under $50 Worth Your Attention and 2 That Underwhelm",
      "id": 138036823,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.",
      "url": "https://finnhub.io/api/news?id=a5b000f119a675be200cdc107286503590cb710304258f4cf0c41eb86cf32b29"
    }
  }
]